
Opinion|Videos|January 17, 2025
Practice Pearls for Managing Patients With Prurigo Nodularis
Author(s)Shawn Kwatra, MD, FAAD
A panelist discusses how the advent of targeted systemic therapies such as dupilumab and nemolizumab has transformed the treatment landscape for prurigo nodularis, offering more effective options for breaking the itch-scratch cycle while maintaining favorable safety profiles compared with traditional systemic treatments.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- Based on our discussion today, what key insights or new perspectives could you share regarding treatment considerations for systemic therapies for prurigo nodularis?
- What take-home messages or practice pearls do you have for clinicians treating patients with prurigo nodularis?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
New Review Confirms How Nonmedicated Skin Care Vehicles Drive Clinical Improvement
2
Zasocitinib Shows High Skin Clearance at Hard-to-Treat Psoriasis Sites
3
Dermatology Times Spot Test: July 19, 2026
4
Soficitinib (ICP-332) Meets Primary Endpoint in Phase 3 Trial for Moderate to Severe AD
5











